Dear LAUS Member:

Most patients diagnosed with localized prostate cancer today are curable with radical prostatectomy and/or radiation therapy to the prostate. There is, however, a subgroup of patients who are at high risk of failing local treatment. This population of patients is thus being targeted to ascertain whether the addition of systemic therapy to standard local treatment will show an improved outcome.

This meeting will serve to inform you and your research associates of the rationale, patient eligibility, and procedures for the clinical trial.

Sincerely,

Grannum R. Sant MD, FRCS
Vice President- Urology
US Medical Affairs
Sanofi- Aventis

Speaker: Adam S. Kibel, MD, Washington University, School of Medicine, St. Louis, MO.

Topic: "Clinical Trial Options for Early Stage High Risk Prostate Cancer Patients: A Focus on TAX 3501."

At the conclusion of this activity, the participant will be able to: